Literature DB >> 14968353

Retention of lepirudin at the tip of a silicone catheter: a better catheter flush solution?

McDonald K Horne1, Elizabeth Inkellis.   

Abstract

Because central venous catheters often become blocked by clot at their tip despite heparin flushes, a more effective anticoagulant is needed. We hypothesize that lepirudin, a recently introduced protein anticoagulant, might be more effective than heparin because of its tendency to adsorb to silicone, a commonly used catheter material. We preliminarily tested this hypothesis in vitro by measuring residual lepirudin and heparin activity at the tip of a catheter that had been submerged in a flowing stream of water for various periods of time. We observed that lepirudin is less readily removed than heparin from the catheter by fluid washing over it. This "slow-release" property of lepirudin might provide prolonged protection against clot formation at the catheter tip. A clinical trial will be necessary, however, to determine whether this property translates into significant improvement in catheter function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968353     DOI: 10.1007/s00520-004-0592-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  20 in total

1.  Peripheral venous access ports: outcomes analysis in 109 patients.

Authors:  L J Bodner; J L Nosher; K M Patel; R L Siegel; R Biswal; C E Gribbin; R Tokarz
Journal:  Cardiovasc Intervent Radiol       Date:  2000 May-Jun       Impact factor: 2.740

Review 2.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.

Authors:  J Hirsh; T E Warkentin; S G Shaughnessy; S S Anand; J L Halperin; R Raschke; C Granger; E M Ohman; J E Dalen
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

3.  Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

Authors:  A Greinacher; U Janssens; G Berg; M Böck; H Kwasny; B Kemkes-Matthes; P Eichler; H Völpel; B Pötzsch; M Luz
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

4.  Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.

Authors:  G Huhle; U Hoffmann; X Song; L C Wang; D L Heene; J Harenberg
Journal:  Br J Haematol       Date:  1999-07       Impact factor: 6.998

5.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

Authors:  J I Weitz; M Hudoba; D Massel; J Maraganore; J Hirsh
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

6.  Venous access: a prospective, randomized study of the Hickman catheter.

Authors:  L D Wagman; A Kirkemo; M R Johnston
Journal:  Surgery       Date:  1984-03       Impact factor: 3.982

7.  Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients.

Authors:  Christian Rabe; Tobias Gramann; Ximena Sons; Marc Berna; María Angeles González-Carmona; Hans-Ulrich Klehr; Tilman Sauerbruch; Wolfgang H Caselmann
Journal:  Intensive Care Med       Date:  2002-07-05       Impact factor: 17.440

8.  Comparison of heparin and 0.9% sodium chloride injection in the maintenance of indwelling intermittent i.v. devices.

Authors:  J C Garrelts; J LaRocca; D Ast; D F Smith; D E Sweet
Journal:  Clin Pharm       Date:  1989-01

9.  Experience with subcutaneous infusion ports in three hundred patients.

Authors:  T E Brothers; L K Von Moll; J E Niederhuber; J A Roberts; S Walker-Andrews; W D Ensminger
Journal:  Surg Gynecol Obstet       Date:  1988-04

10.  Occlusive thrombus formation on indwelling catheters: in vitro investigation and computational analysis.

Authors:  P Friedrich; A J Reininger
Journal:  Thromb Haemost       Date:  1995-01       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.